OPC Pharmaceutical JSC Income Statement

Financials in millions VND. Fiscal year is January - December.

Millions VND. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,128,779	1,122,987	968,576	1,004,887	1,171,614	1,123,728
Revenue Growth (YoY)	17.84%	15.94%	-3.61%	-14.23%	4.26%	16.38%
Cost of Revenue	602,297	591,453	522,458	526,456	637,906	643,499
Gross Profit	526,482	531,534	446,118	478,431	533,708	480,229
Selling, General & Admin	400,260	399,245	311,684	332,311	355,073	313,516
Operating Expenses	400,260	399,245	311,684	332,311	355,073	313,516
Operating Income	126,222	132,289	134,434	146,120	178,636	166,713
Interest Expense	-	-	-	-334.55	-925.2	-4,819
Interest & Investment Income	11,792	11,916	8,335	15,854	7,813	3,707
Earnings From Equity Investments	1,960	1,932	1,535	838.45	797.74	172.88
Currency Exchange Gain (Loss)	891.39	861.55	448.73	555.41	279.37	360.84
Other Non Operating Income (Expenses)	-5,281	-6,114	-7,627	-7,710	-6,677	-6,894
EBT Excluding Unusual Items	135,585	140,885	137,126	155,323	179,924	159,241
Gain (Loss) on Sale of Investments	7,159	7,159	-	-	-	-
Pretax Income	142,743	148,043	137,126	155,323	179,924	159,241
Income Tax Expense	30,645	31,623	27,672	33,004	37,530	35,878
Earnings From Continuing Operations	112,098	116,420	109,454	122,319	142,394	123,363
Minority Interest in Earnings	-598.53	-539.6	-2,394	-84.74	-266.22	3,014
Net Income	111,500	115,881	107,060	122,234	142,128	126,377
Preferred Dividends & Other Adjustments	16,136	17,382	12,652	18,677	14,010	13,416
Net Income to Common	95,364	98,499	94,408	103,557	128,118	112,961
Net Income Growth	12.47%	8.24%	-12.41%	-14.00%	12.46%	19.46%
Shares Outstanding (Basic)	64	64	64	64	64	64
Shares Outstanding (Diluted)	64	64	64	64	64	64
Shares Change (YoY)	-	-	-	-	-	-0.00%
EPS (Basic)	1488.88	1537.82	1473.95	1616.80	2000.25	1763.61
EPS (Diluted)	1488.88	1537.82	1473.95	1616.80	2000.00	1763.61
EPS Growth	6.73%	4.33%	-8.83%	-19.16%	13.40%	19.16%
Free Cash Flow	-39,475	41,675	12,147	243,317	28,688	181,809
Free Cash Flow Per Share	-616.30	650.66	189.65	3798.80	447.90	2838.51
Dividend Per Share	-	-	-	1500.000	1500.000	-
Gross Margin	46.64%	47.33%	46.06%	47.61%	45.55%	42.73%
Operating Margin	11.18%	11.78%	13.88%	14.54%	15.25%	14.84%
Profit Margin	8.45%	8.77%	9.75%	10.30%	10.94%	10.05%
Free Cash Flow Margin	-3.50%	3.71%	1.25%	24.21%	2.45%	16.18%
EBITDA	147,722	153,844	156,735	169,015	201,454	189,215
EBITDA Margin	13.09%	13.70%	16.18%	16.82%	17.20%	16.84%
D&A For EBITDA	21,500	21,555	22,301	22,895	22,819	22,502
EBIT	126,222	132,289	134,434	146,120	178,636	166,713
EBIT Margin	11.18%	11.78%	13.88%	14.54%	15.25%	14.84%
Effective Tax Rate	21.47%	21.36%	20.18%	21.25%	20.86%	22.53%
Revenue as Reported	1,128,779	1,122,987	968,576	1,004,887	1,171,614	1,123,728
Advertising Expenses	-	66,590	43,302	51,343	48,858	40,148

Source: S&P Global Market Intelligence. Standard template. Financial Sources.